ISM9528 not checked
InSilico Medicine Hong Kong Limited
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ISM9528 capsules will be orally administered as per the schedule specified in the protocol.”In the company’s words, NCT07932041 on ClinicalTrials.gov
- Main trialPhase 1
- “This is an open-label, phase 1, sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of ISM9528 in healthy adult.”In the company’s words, NCT07932041 on ClinicalTrials.gov
Coming up1
- 3 DecPhase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07932041
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 3 Dec 2026 | A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM9528 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026